Prävention der Präeklampsie

T. Fischer; S. Pildner von Steinburg; F. Diedrich; P. Neumaier-Wagner; S. Paepke; V. R. Jacobs; K. T. M. Schneider

doi:10.1055/s-2005-836321

Zentralblatt für Gynäkologie, Inhaltsverzeichnis

Zentralbl Gynakol 2005; 127(2): 83-90
DOI: 10.1055/s-2005-836321

Originalarbeit

Prävention der Präeklampsie

Prevention of PreeclampsiaT. Fischer¹ , S. Pildner von Steinburg¹ , F. Diedrich¹ , P. Neumaier-Wagner¹ , S. Paepke¹ , V. R. Jacobs¹ , K. T. M. Schneider¹

¹Frauenklinik der Technischen Universität München, Klinikum rechts der Isar

Auszugsweise vorgestellt als Vortrag „Präeklampsie - Prophylaxe und neue Therapieansätze” auf dem Symposium „Aktueller Stand und Perspektiven in Gynäkologie und Geburtshilfe - für Klinik und Praxis” anlässlich des 70. Geburtstages von Herrn Professor Dr. Hermann Hepp, München/Großhadern Februar 2004

Abstract

Zusammenfassung

Die Präeklampsie zeichnet sich durch eine hohe fetale und maternale Morbidität und Mortalität aus und ist in hohem Maße für die Frühgeburtlichkeit verantwortlich. Trotz der klinischen Bedeutung konnten die pathophysiologischen Mechanismen bis heute nicht abschließend geklärt werden. Demzufolge sind auch kausale bzw. präventive Therapiestrategien nicht ausreichend bekannt. Eine zufriedenstellende Erfahrung in der Prävention einer Präeklampsie liegt bisher nur für die Anwendung von Acetylsalicylsäure (ASS) in Risikokollektiven vor. ASS greift direkt in die Dysbalance des vasodilatierenden Prostazyklins und des vasokonstringierenden Thromboxans ein. Erste Studien beweisen darüber hinaus auch einen präventiven Effekt der Antioxidanzien Vitamin C und E. Eine frühzeitige antihypertensive Therapie kann dagegen eine spätere Progression der Erkrankung nicht positiv beeinflussen. Eine Natriumrestriktion, eine Kalzium- und Magnesiumsubstitution, die Gabe von Fischöl oder eine Steroidtherapie sind in der Prävention einer Präeklampsie unwirksam. Die zukünftige Klärung der pathophysiologischen Zusammenhänge der Präeklampsie könnte helfen, die Akuttherapie zu verbessern und gleichzeitig wirksame präventive Strategien zu entwickeln.

Abstract

Preeclampsia is accompanied by high fetal and maternal morbidity and mortality and to a high degree responsible for preterm delivery. The pathophysiologic mechanisms underlying this disease remain poorly understood. Accordingly, only few causative or preventive therapeutical strategies are known. One such example for a preventive strategy is the use of aspirin (ASA) which directly affects the imbalance of vasodilative prostacycline and vasoconstrictive thromboxane. Recently, some studies are indicating a preventive effect of vitamin C and E substitution. In contrast, early antihypertensive therapy did not prevent later progression of the disease. Furthermore, sodium restriction, calcium and magnesium substitution, fish oil substitution, or steroid therapy are without any effect regarding the later development of preeclampsia. It is of utmost importance to further elucidate underlying pathophysiological mechanisms to improve therapeutical and preventive strategies.

Schlüsselwörter

Präeklampsie - HELLP-Syndrom - Prävention - pathophysiologische Mechanismen - Acetylsalicylsäure - Heparin

Key words

Preeclampsia - HELLP syndrome - prevention - pathophysiology - acetyl salicylic acid - heparin

Volltext

Referenzen

Literatur

1 Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systemic review. Eur J Obstet Gynecol Reprod Biol. 2002; 101 6-14
2 Bates S M, Greer I A, Hirsh J, Ginsberg J S. Use of antithrombotic agents during pregnancy. Chest. 2004; 126 (3 Suppl) 627S-644S
3 Baylis C, Beinder E, Suto T, August P. Recent insights into the roles of nitric oxide and renin-angiotensin in the pathophysiology of preeclamptic pregnancy. Semin Nephrol. 1998; 18 208-230
4 Beinder E, Mohaupt M. NO-Donatoren zur Verhütung und Behandlung präeklamptischer Erkrankungen. Gynakologe. 1999; 32 768-775
5 Beinder E, Mohaupt M, Schlembach D, Fischer T, Sterzel R B, Lang N, Baylis C. Nitric oxide synthase activity and doppler parameters in the fetoplacental and uteroplacental circulation in preeclampsia. Hypertens Pregnancy. 1999; 18 115-127
6 Belfort M A, Moise K J. Effect of magnesium sulfate on maternal brain blood flow in preeclampsia: a randomized, placebo-controlled study. Am J Obstet Gynecol. 1992; 167 661-666
7 Bootstaylor B S, Roman C, Parer J T, Heymann M A. Fetal and maternal hemodynamic and matabolic effects of maternal nitroglycerin infusions in sheep. Am J Obstet Gynecol. 1997; 176 644-650
8 Boulanger C, Luscher T F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990; 85 587-590
9 Boy K, Zimmermann U, Wildt L. Enhanced tumor necrosis factor alpha (TNF alpha) secretion by stimulated mononuclear leucocytes in gestosis (abstract). Exp Clin Endocinol Diabetes. 1995; 103 (Suppl 1) 42
10 Bucher H C, Guyatt G H, Cook R J, Hatala R, Cook D J, Lang J D, Hunt D. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a metaanalysis of rendomized controlled trials. JAMA. 1996; 275 1113-1117
11 Bussolino F, Camussi G. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation. Prostaglandins. 1980; 20 781-791
12 Carbonne B, Jannet D, Touboul C, Khelifati Y, Milliez J. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol. 1993; 81 908-914
13 Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost. 2003; 1 433-438
14 Chappell L C, Seed P T, Briley A L, Kelly F J, Lee R, Hunt B J, Parmar K, Bewley S J, Shennan A H, Steer P J, Poston L. Effect of antioxidants on the occurrence of pre-eclampsia in women at incresaed risk: a randomised trial. Lancet. 1999; 354 810-816
15 CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group . CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9 364 pregnant women. Lancet. 1994; 343 619-629
16 Coomarasamy A, Papaioannou S, Gee H, Khan K S. Aspririn for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis. Obstet Gynecol. 2001; 98 861-866
17 Cotton D B, Hallak M, Janusz C, Irtenkauf S M, Berman R F. Central anticonvulsant effects of magnesium sulfate on N-methyl-D-aspartate-induced seizures. Am J Obstet Gynecol. 1993; 168 974-978
18 Cruickshank D J, Robertson A A, Campbell D M, MacGillivray I. Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. Eur J Obstet Gynecol Reprod Biol. 1992; 45 47-51
19 Dekker G, Sibai B. Primary, secondary, and tertiary prevention of preeclampsia. Lancet. 2001; 357 209-215
20 Del Rio G, Velardo A, Zizzo G, Avogaro A, Cipolli C, Della Casa L, Marrama P, MacDonald I A. Effect of estradiol on the sympathoadrenal response to mental stress in normal men. J Clin Endocrinol Metab. 1994; 79 836-840
21 DiSessa T G, Moretti M L, Khoury A, Pulliam D A, Arheart K L, Sibai B M. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol. 1994; 171 892-900
22 Duggan P M, McCowan L M, Stewart A W. Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension. Aust N Z J Obstet Gynaecol. 1992; 32 335-338
23 Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ. 2001; 322 329-333
24 Ettinger S M, Silber D H, Gray K S, Smith M B, Yang Q X, Kunselman A R, Sinoway L I. Effects of the ovarian cycle on sympathetic neural outflow during static exercise. J Appl Physiol. 1998; 85 2075-2081
25 England L J, Levine R J, Qian C, Morris C D, Sibai B M, Catalano P M, Curet L B, Klebanoff M A. Smoking before pregnancy and risk of gestational hypertension and preeclampsia. Am J Obstet Gynecol. 2002; 186 1035-1040
26 Fischer T, Krause M, Beinder E, Schlembach D, Rabenbauer B, Wildt L, Lang N. Schwangerschaftsverlängerung bei Patientinnen mit HELLP-Syndrom. Geburtshilfe Frauenheilkd. 1999; 59 335-345
27 Fischer T, Schneider M P, Schobel H P, Heusser K, Langenfeld M, Schmieder R E. Vascular reactivity in patients with preeclampsia and HELLP syndrome. Am J Obstet Gynecol. 2000; 183 1489-1494
28 Fischer T, Schobel H P, Frank H, Andreae M, Schneider K T, Heusser K. Pregnancy-induced sympathetic overactivity: a precursor of preeclampsia. Eur J Clin Invest. 2004; 34 443-448
29 Fischer T, Heusser K, Schobel H. Autonomes Nervensystem und Präeklampsie. Zentrlbl Gynäkol. 1999; 121 603-607
30 Fischer T, Wildt L. Glukokortikoide und HELLP-Syndrom - Eine Standortbestimmung. Gynakologe. 1999; 32 783-790
31 Fischer T, Wallukat G, Schneider M P, Schlembach D, Munz W, Homuth V. HELLP syndrome in the 18^th week of gestation in association with elevated angiotensin AT(1)-receptor autoantibodies. Eur J Obstet Gynecol Reprod Biol. 2001; 97 255-257
32 Goldman R S, Finkbeiner S M. Therapeutic use of magnesium sulfate in selected cases of cerebral ischemia and seizure. N Engl J Med. 1988; 319 1224-1225
33 Gris J C, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland M L, Dauzat M, Mares P. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004; 103 3695-3699
34 Gruppo di Studio Ipertensione in Gravidanza . Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br J Obstet Gynaecol. 1998; 105 718-722
35 Harper A, Murnaghan G A. Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol. Br J Obstet Gynaecol. 1991; 98 453-459
36 Hasbargen U, Hasler M, Sattler C, Kolben M. Low incidence of HELLP syndrome before 32^nd week of pregnancy: discontinuation of the Munich study. Z Geburtshilfe Neonatol. 2000; 204 78-79
37 He X R, Wang W, Crofton J T, Share L. Effects of 17beta-estradiol on sympathetic activity and pressor response to phenylephrine in ovariectomized rats. Am J Physiol. 1998; 275 1202-1208
38 Heilmann L, Hojnacki E, Spanuth E. Hämostase und Präeklampsie. Geburtshilfe Frauenheilkd. 1991; 51 223-227
39 Hjertberg R, Belfrage P, Hanson U. Conservative treatment of mild and moderate hypertension in pregnancy. Acta Obstet Gynecol Scand. 1992; 71 439-446
40 Holzgreve W, Li J J, Steinborn A, Kulz T, Sohn C, Hodel M, Hahn S. Elevation in erythroblast count in maternal blood before the onset of preeclampsia. Am J Obstet Gynecol. 2001; 184 165-168
41 Imperiale T F, Petrulis A S. A meta-analysis of low dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA. 1991; 266 260-264
42 Janes S L, Kyle P M, Redman C, Goodall A H. Flow cytometric detection of activated platelets in pregnant women prior to the development of pre-eclampsia. Thromb Haemost. 1995; 74 1059-63
43 Klockenbusch W, Löbbecke K. Präventiv-therapeutische Möglichkeiten. In: Klockenbusch W, Fischer T (Hrsg). Präeklampsie. Uni-Med Verlag, Bremen, London, Boston 2004; 70-76
44 Klockenbusch W, Rath W. Prävention der Präeklampsie mit Acetylsalicylsäure - eine kritische Analyse. Z Geburtshilfe Neonatol. 2002; 206 125-130
45 Kupferminc M J, Fait G, Many A, Lessing J B, Yair D, Bar-Am A, Eldor A. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001; 20 25-44
46 Lachmeijer A M, Dekker G A, Pals G, Aarnoudse J G, ten Kate L P, Arngrimsson R. Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol. 2002; 105 94-113
47 Lees C, Valensise H, Black R, Harrington K, Byiers S, Romanini C, Campbell S. The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of pre-eclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol. 1998; 12 334-338
48 Leitich H, Egarter C, Husslein P, Kaider A, Schemper M. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. Br J Obstet Gynaecol. 1997; 104 450-459
49 Levine R J, Hauth J C, Curet L B, Sibai B M, Catalano P M, Morris C D, DerSimonian R, Esterlitz J R, Raymond E G, Bild D E, Clemens J D, Cutler J A. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997; 337 69-76
50 Lydakis C, Lip G Y, Beevers M, Beevers D G. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999; 12 541-547
51 Magee L A, Schick B, Donnenfeld A E, Sage S R, Conover B, Cook L, McElhatton P R, Schmidt M A, Koren G. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol. 1996; 174 823-828
52 Mahmoud T Z, Bjornsson S, Calder A A. Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome. Eur J Obstet Gynecol Reprod Biol. 1993; 50 109-113
53 Martin J N, Perry K G, Miles J F, Blake P G, Magann E F, Roberts W E, Martin R W. The interrelationship of eclampsia, HELLP syndrome, and prematurity: cofactors for significant and perinatal risk. Br J Obstet Gynaecol. 1993; 100 1095-1100
54 Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam S S. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1993; 168 152-156
55 Moretti M M, Fairlie F M, Akl S, Khoury A D, Sibai B M. The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. Am J Obstet Gynecol. 1990; 163 1844-1848
56 Morrison E R, Miedzybrodzka Z H, Campbell D M, Haites N E, Wilson B J, Watson M S, Greaves M, Vickers M A. Prothrombic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large poulation-based study and systematic review. Thromb Haemost. 2002; 87 779-785
57 Nakaki T, Nakayama M, Kato R. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol. 1990; 189 347-353
58 Olsen S F, Secher N J, Tabor A, Weber T, Walker J J, Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. BJOG. 2000; 107 382-395
59 Pickles C J, Symonds E M, Broughton Pipkin F. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol. 1989; 96 38-43
60 Pirhonen J P, Erkkola R U, Ekblad U U. Uterine and fetal flow velocity waveforms in hypertensive pregnancy: the effect of a single dose of nifedipine. Obstet Gynecol. 1990; 76 37-41
61 Plouin P F, Breart G, Llado J, Dalle M, Keller M E, Goujon H, Berchel C. A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. Br J Obstet Gynaecol. 1990; 97 134-141
62 Rey E. Effects of methyldopa on umbilical and placental artery blood flow velocity waveforms. Obstet Gynecol. 1992; 80 783-787
63 Redman C W. Immunological aspects of pre-eclampsia. Baillieres Clin Obstet Gynaecol. 1992; 6 601-615
64 Redman C W, Roberts J M. Management of pre-eclampsia. Lancet. 1993; 341 1451-1454
65 Reubinoff B E, Schenker J G. HELLP-Syndrome - a syndrome of hemolysis, elevated liver enzymes and low platelet count - complicating preeclampsia-eclampsia. Int J Gynaecol Obstet. 1991; 36 95-102
66 Richichi J, Vasilenko P. The effects of nifedipine on pregnancy outcome and morphology of the placenta, uterus, and cervix during late pregnancy in the rat. Am J Obstet Gynecol. 1992; 167 797-803
67 Schlembach D, Beinder E, Zingsem J, Wunsiedler U, Beckmann M W, Fischer T. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth retardation. Clin Sci. 2003; 105 279-285
68 Schobel H P, Fischer T, Heuszer K, Geiger H, Schmieder R E. Preeclampsia - A state of sympathetic overactivity. N Engl J Med. 1996; 335 1480-1485
69 Schobel H P, Fischer T. The autonomic nervous system in normal and hypertensive pregnancy. In: Rubin C (Ed). Handbook of Hypertension. Vol. 21. Hypertension in Pregnancy. 2nd ed. 2000; 76-90
70 Sibai B M, Gonzalez A R, Mabie W C, Morretti M. A comparison of labetalol plus hospitilization versus hospitilization alone in the management of preeclampsia remote from term. Obstet Gynecol. 1987; 70 323-327
71 Sibai B M, Mabie W C, Shamsa F, Villar M A, Anderson G D. A comparison of no medication versus methydopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990; 162 960-967
72 Sibai B M, Barton J R, Akl S, Sarinoglu C, Mercer B M. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol. 1992; 167 879-884
73 Skrabal F, Kotanko P, Lueger A Goedde B, Balmes R, Barenbrock M, Fischer T. Augmented reciprocal α-2 and β-2 adrenoceptor changes and rise of total peripheral resistance during increase of salt intake in salt-sensitive humans. In: Rettig R, Ganten D, Luft FC (Hrsg). Salt and Hypertension. Springer, Berlin, New York 1989; 128-138
74 Spätling L, Spätling G. Magnesium supplementation in pregnancy. A double-blind study. Br J Obstet Gynaecol. 1988; 95 120-125
75 Thaler I, Amit A, Jakobi P, Itskovitz-Eldor J. The effect of isosorbide dinitrate on uterine artery and umbilical artery flow velocity waveforms at mid-pregnancy. Obstet Gynecol. 1996; 88 838-843
76 The Eclampsia Trial Collaborative Group . Which anticonvulsant for woman with eclampsia? Evidence from the collaborative eclampsia trial. Lancet. 1995; 345 1455-1463
77 Altmany D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D. The Magpie Trial Collaborative Group . Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002; 359 1877-1890
78 Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J. Low dose acetylsalicylic acid in prevention of pregnany-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG. 2002; 109 161-167
79 Vetter K, Kilavuz Ö. Dopplersonographie und Präeklampsie. Gynakologe. 1999; 32 761-767
80 Dadelszen P von, Ornstein M P, Bull S B, Logan A G, Koren G, Magee L A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000; 355 87-92
81 Wagner P M, Heyl W, Rath W. Die Bedeutung von Stickstoffmonoxid in der Pathophysiologie und Therapie der Präeklampsie. Geburtshilfe Frauenheilkd. 2000; 60 1-10
82 Waismann G D, Mayorga L M, Camera M I, Vignolo C A, Martinotti A. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia?. Am J Obstet Gynecol. 1988; 159 308-309
83 Wallenburg H C. Prevention of preeclampsia: status and perspectives 2000. Eur J Obstet Gynecol Reprod Biol. 2001; 94 13-22
84 Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen J W, Haller H, Luft F C. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1-receptor. J Clin Invest. 1999; 103 945-952
85 Wide-Swensson D H, Ingemarsson I, Lunell N O, Forman A, Skajaa K, Lindberg B, Lindeberg S, Marsal K, Andersson K E. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. Am J Obstet Gynecol. 1995; 173 872-878
86 Zhang J, Klebanoff M A, Levine R J, Puri M, Moyer P. The puzzling association between smoking and hypertension during pregnancy. Am J Obstet Gynecol. 1999; 181 1407-1413

Für die Autoren der Projektgruppe Präeklampsie der Technischen Universität München:

Priv.-Doz. Dr. med. Thorsten FischerLtd. Oberarzt und stellvertretender Abteilungsleiter Perinatalmedizin

Frauenklinik der Technischen Universität München · Klinikum rechts der Isar

Ismaninger Str. 22

81675 München

Telefon: 0 89/41 40/24 30

Fax: 0 89/41 40/24 47